Pharmacological Treatments Available for Immune‐ Checkpoint‐Inhibitor‐Induced Colitis

Abstract

Immune checkpoint inhibitor treatment has shown revolutionary therapeutic effects in various carcinomas. However, immune‐related adverse events (irAE) following this treatment can sometimes lead to treatment discontinuation. One such frequently encountered adverse event is immune‐related colitis (irAE colitis). Corticosteroids (CS) are the first‐line treatment for irAE colitis, but we often encounter CS‐refractory or ‐resistant cases. The application of multiple biologics has been proposed as a therapy to be administered after CS treatment; however, the efficacy and safety of biologics for patients with irAE colitis who do not respond to CS have not been established. This review summarizes the treatment regimens available for irAE colitis, focusing on the mechanism of action of corticosteroids, infliximab, vedolizumab, and other drugs.